A recent Geriatric Medicine digest,
as sent to subscribers

Study Type: Single-city interrupted time-series analysis (segmented Poisson regression), using routinely collected municipal data.

Key Question: Was a municipal frailty screening-based health guidance programme associated with a change in long-term care (LTC) certification rates among adults aged ≥75 years?

Key Findings:

• Post-intervention, the trend in age-standardised LTC certification declined relative to the pre-intervention trend (annualised RR for trend change 0.974; 95% CI 0.963–0.983).
• By end of follow-up (December 2025), the estimated rate was 6.8% lower than the counterfactual projected from the pre-intervention trend (95% CI 4.4–10.0%).
• Data covered January 2015 to December 2025, with a slope change assumed 12 months after programme start (April 2022).

Clinical Relevance: Offers population-level, hypothesis-generating evidence for linking frailty screening to preventive guidance, relevant to NHS discussions on proactive frailty identification and prevention of social care need, though the Japanese LTC system is not directly comparable.

Limitations: Single-city design with no control series makes it vulnerable to confounding from concurrent events (e.g. COVID-19 effects on service use and certification), so causality cannot be inferred.

Study Type: Randomised, three-arm, parallel-group clinical trial (single acute geriatric ward setting).

Key Question: Does adding immersive virtual reality to a multicomponent exercise programme (MEP) improve functional outcomes in hospitalised older adults compared with conventional MEP or usual care?

Key Findings:

• 156 participants (mean age 86.4 years). SPPB improved with MEP vs usual care (+1.04 points; 95% CI 0.33–1.75), but not with MEP-VR vs usual care (+0.13; 95% CI -0.64 to 0.89). MEP outperformed MEP-VR directly (0.91 points; 95% CI 0.16–1.67).
• MMSE improved in both arms vs usual care (MEP-VR +1.90, 95% CI 0.76–3.04; MEP +1.23, 95% CI 0.18–2.28); MEP-VR vs MEP was non-significant (+0.67; 95% CI -0.46 to 1.80).
• Adherence was high, with no serious VR-related adverse events.

Clinical Relevance: Supports conventional in-hospital MEP over VR-enhanced delivery for preventing functional decline; VR cannot currently justify resource investment on NHS geriatric wards.

Limitations: The cognitive findings are secondary outcomes with no direct MEP-VR vs MEP difference, so they are hypothesis-generating only.

Study Type: Retrospective cohort study (Irish primary care data, 44 general practices; 35,942 community-dwelling adults aged ≥65; 2012–2016)

Key Question: What is the prevalence of STOPPFall-defined fall-risk-increasing drugs (FRIDs) in older community-dwelling adults, how are they associated with fall-related admission, and does prescribing change after admission?

Key Findings:

• 47% were prescribed ≥1 long-term FRID at baseline; 2.4% had a subsequent fall-related admission.
• Long-term FRID use was associated with fall-related admission (aHR 2.85, 95% CI 2.13–3.82), with a graded effect: one FRID aHR 2.81; ≥5 FRIDs aHR 5.67 (95% CI 3.70–8.70).
• FRID prevalence was essentially unchanged after admission (53.9% vs 53.2%); only 19.5% had a FRID discontinued, while 14.5% had a new FRID started.

Clinical Relevance: Fall-related admission appears to be a missed opportunity for deprescribing, supporting structured medication review (e.g. STOPPFall) within UK post-fall and discharge pathways.

Limitations: Observational design with confounding by indication likely, and data from 2012–2016 in an Irish primary care setting may limit generalisability to current UK practice.

Study Type: Randomised clinical trial (secondary outcomes analysis)

Key Question: Does adding motor learning (timing and coordination) components to standard exercise improve the motor skill of walking more than standard exercise alone in community-dwelling older adults with walking problems?

Key Findings:

• No between-group differences in oxygen cost of walking, gait variability, smoothness or walk ratio at 12, 24 or 36 weeks (n = 249; mean age 77.4 years; baseline speed 1.07 m/s). The only significant difference, stance time variability at 24 weeks (P = .015), was likely spurious.
• Oxygen cost of walking improved in both arms (approximately -0.04 to -0.05 ml/kg·m, P < .0001) and was sustained at 36 weeks, 24 weeks after supervised exercise ended.

Clinical Relevance: Standard exercise alone appears sufficient to improve walking efficiency in this population, so adding resource-intensive motor learning components to NHS falls and mobility programmes is not supported by these outcomes.

Limitations: This is a secondary analysis in higher-functioning participants (baseline speed >1.0 m/s), and the lack of a no-exercise control means improvements cannot be attributed to the interventions with certainty.

Study Type: Nationwide registry-based retrospective cohort study (Finland, 2004–2018; n = 9,001)

Key Question: Is pre-surgery statin use associated with mortality, reoperation and length of stay after surgical evacuation of chronic subdural haematoma?

Key Findings:

• Statin users (27.2%) had lower adjusted 30-day mortality (3.3% vs 4.5%; HR 0.57, 95% CI 0.44–0.73) and 1-year mortality (13.3% vs 15.4%; HR 0.66, 95% CI 0.58–0.75).
• Reoperation rates did not differ at 30 days (sub-distribution HR 1.08, 95% CI 0.97–1.21) or 1 year (1.09, 0.96–1.22).
• Hospital stay was shorter in statin users (22.1 vs 26.3 days, adjusted P = .002), though SDs were very large.

Clinical Relevance: Supports continuing statins in older patients with cSDH, though it does not justify initiating them for this indication, which is relevant to peri-operative medication decisions in NHS neurosurgical and orthogeriatric-style co-management.

Limitations: Observational design with residual confounding likely (healthy-user bias, frailty, comorbidity), so the association cannot be taken as causal.

Study Type: Retrospective linked cohort study (n=944), Nova Scotia, Canada.

Key Question: How do one-year physician service costs vary by Clinical Frailty Scale category once differential survival is accounted for?

Key Findings:

• 41.6% of ED-referred older adults (mean age 80.8) died within one year; physician costs were concentrated in the first months after presentation.
• Mildly and moderately frail patients cost ~$300–$400 more than well patients (imprecise estimates). Severely frail patients cost $704 less over one year, driven mainly by shorter survival.
• During periods alive, all frailty groups incurred higher costs than well patients.

Clinical Relevance: Lower cumulative spend in severe frailty should not be read as lower need, supporting early frailty identification to prompt proactive multidisciplinary, supportive or palliative care in NHS pathways.

Limitations: Single-province cohort of ED-referred patients with physician service costs only (excluding inpatient, community and social care), limiting generalisability to UK settings.

Study Type: Multicohort longitudinal observational study (CLHLS, HRS, ELSA; supplementary SHARE analysis)

Key Question: Are plant-based dietary patterns, and their quality, associated with frailty risk in older adults?

Key Findings:

• Higher overall plant-based diet index was associated with lower frailty risk in all three cohorts (OR 0.71–0.80); higher unhealthful plant-based index was associated with higher risk (OR 1.24–1.41).
• Healthful index was inversely associated with frailty only in ELSA (null in CLHLS and HRS). Where repeated diet data allowed, between-person differences showed stronger associations than within-person change.
• Nuts, vegetables and plant oils showed predominantly inverse associations across frailty domains; spline analysis showed limited non-linearity.

Clinical Relevance: Supports counselling on diet quality rather than plant-based status alone, including in UK-relevant ELSA data, though it does not establish causation.

Limitations: Observational design with diet-frailty associations that may reflect residual confounding or reverse causation, and inconsistent healthful-index findings across cohorts.

Study Type: National research priority-setting exercise (survey-based consultation with Delphi-style ranking), following established prioritisation frameworks.

Key Question: What should be the priority research questions for dementia and brain health in Scotland, according to people with lived experience, carers, the public and professionals?

Key Findings:

• 706 participants submitted 2677 questions, consolidated to 142; two Delphi-style ranking rounds (n=242, n=252) produced a final list of 20 (10 brain health, 10 dementia).
• Risk reduction was a leading brain health priority; early diagnosis was a top dementia priority.
• Brain resilience and improving dementia care pathways were rated as having greatest potential impact.

Clinical Relevance: The list gives Scottish researchers and funders a patient- and carer-informed agenda that can guide study design and local service development, though findings may inform UK-wide priorities.

Limitations: Only 6.8% of participants had cognitive impairment themselves (versus 37% public contributors), so the priorities may under-represent the views of people living with dementia.